Stockwinners Market Radar for March 30, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:19 EDT Pedevco CEO buys $247K in common stock - In a regulatory filing, Pedevco disclosed that its CEO Simon Kukes bought 264K shares of common stock on March 30th in a total transaction size of $247K.

20:04 EDT Cathie Wood's ARK Investment bought 461.9K shares of SomaLogic today

19:36 EDT Biogen announces detailed analyses from phase 2 study of Lecanemab - Eisai (ESALY) and Biogen (BIIB) announced that three additional detailed analyses from the Phase IIb clinical study , evaluating the efficacy and safety of lecanemab for mild cognitive impairment due to Alzheimer's disease and mild AD , were published in the peer-reviewed journals. Study 201 was a multicenter, double-blind, placebo-controlled, Phase 2b trial conducted in 856 patients with early AD. Its core study evaluated key efficacy assessments, including clinical change on the AD Composite Score as the primary endpoint at 12 months and as key secondary endpoints, ADCOMS, Clinical Dementia Rating-Sum-of-Boxes and AD Assessment Scale-Cognitive Subscale 14 at 18 months. Following analysis of the 18-month core phase, an intervening off-treatment period ranging from 9-59 months was taken, which was followed by an OLE with 10 mg/kg IV bi-weekly lecanemab dosing to assess long-term safety and tolerability. The results of the primary analysis in the core study including clinical efficacy and biomarkers have already been published, showing a consistent reduction in clinical decline across several clinical and biomarker endpoints with lecanemab 10 mg/kg bi-weekly dosing. Detailed results on biomarker, cognitive, and clinical effects from Study 201: "Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. In the core 201 study, lecanemab was shown to reduce brain Abeta accumulation measured by amyloid PET in a dose- and time-dependent manner after 12 and 18 months of treatment, and corresponding changes in plasma biomarkers and reduction in clinical decline. During the gap period, a trend was observed for plasma Abeta42/40 ratio and p-tau181 values to return to the pre-administration levels (re-accumulation) faster than amyloid PET. In the OLE, lecanemab 10 mg/kg biweekly treatment showed a decrease in brain amyloid beta (Abeta) accumulation measured by amyloid PET, a decrease in the plasma Abeta42/40 ratio, and a decrease in plasma p-tau181. The potential for disease modification with lecanemab is supported by an increasing difference in clinical measures between the lecanemab group and placebo group in line with time during the core period, differences in clinical progression between subjects who received 10 mg/kg lecanemab and those who received placebo in the core period, which remained persistent throughout the gap period, and an impact on biological measures that reflect key pathophysiological changes in AD. Furthermore, the results showed the potential for monitoring the treatment effects of lecanemab using plasma biomarkers. Consistency of efficacy results across various clinical measures and statistical methods in Study 201: In order to assess the robustness of lecanemab's efficacy in Study 201, sensitivity analyses were performed using several statistical models for three key clinical endpoints (ADCOMS, CDR-SB, ADAS-Cog14). The sensitivity analysis showed that 18 months of lecanemab treatment consistently reduced the clinical decline in all statistical models examined. The results of all sensitivity analyses for three key clinical endpoints at the highest dose (10 mg/kg bi-weekly) at 18 months were consistent, with a 29.1% to 37.4% reduction in clinical deterioration with lecanemab compared to placebo for ADCOMS, 26.5% to 38.4% for CDR-SB and 37.4% to 55.9% for ADAS-Cog14. 3. ARIA profile in Study 201: In the core study 201, amyloid-related imaging abnormalities-edema (ARIA-E) was dose dependent, with an incidence 9.9% at the highest doses (10 mg/kg bi-weekly) for the overall population and 14.3% for ApoE4 positive subjects. Most ARIA-E occurred within 30 days after the initial dose and had mild to moderate severity in radiographic severity. Symptomatic ARIA-E occurred in 3% of participants in the 10mg/kg bi-weekly treatment group. ARIA cerebral microhemorrhages, intracerebral hemorrhage greater than1cm, and superficial siderosis (ARIA-H) occurred in 6.2% of subjects who received 10 mg/kg biweekly lecanemab and those events were mostly mild in severity. There were no symptomatic cases of ARIA-H reported in the core study. Overall ARIA-E events in the OLE phase were generally consistent with the rate seen in the lecanemab 10 mg/kg biweekly group in the core study. As with the core study, most ARIA-E occurred within 3 months after receiving the initial dose in the OLE and had mostly mild to moderate in radiographic severity. ARIA-H events in the OLE were generally consistent with the rate seen in the lecanemab 10 mg/kg biweekly group in the core study. ARIA-H events were mostly mild or moderate in severity. One symptomatic case of ARIA-H, intracerebral hemorrhage greater than 1cm, was reported in OLE. This subject did not have concurrent ARIA-E, and the adverse event resolved with residual visual field defect. PK/PD modeling showed that the incidence of ARIA-E was correlated with Cmax at steady state. Based on the fact that lecanemab was generally well tolerated at the highest dose in this study, the Phase 3 Clarity AD study was conducted without dose titration. A subcutaneous formulation that may potentially reduce the Cmax of lecanemab is being developed and evaluated to determine if there is a reduction of the incidence of ARIA-E compared to intravenous formulation."

18:51 EDT Cano Health's Barry Sternlicht resigns from board - Barry Sternlicht issued the following statement announcing his resignation, effective immediately, from the Board of Directors of Cano Health. The letter states: "Dear Marlow and Fellow Board Members: I hereby give notice of my resignation from the Board of Directors of Cano Health, Inc. effective immediately. As you all know, since June 4, 2021 when we closed the merger of JAWS Acquisition Corp. with Cano Health, and Cano officially became a public company, I have worked tirelessly to support the Company's mission and help it become a professionally run public company. I believed in Cano's mission of providing high quality health care to the largely underserved and was impressed by the personal story, the passion and conviction of its CEO, Marlow Hernandez. I personally invested $50 million of the $800 million PIPE we raised from blue chip investors/shareholders like Fidelity, Third Point, Maverick, BlackRock and Owl Creek who shared my passion and enthusiasm for the firm. In total, we handed the company in excess of $1.4 billion in June 2021, less than two years ago. Fast forward to today, this management team has expended nearly all this cash and the Company has not enjoyed any demonstrable improvement in its core profitability. My interests are 100% aligned with the shareholders. The directors who have voiced serious concerns about the status quo have much more at stake in the Company, respectively, than the other members of the Board who appear willing to support the CEO at any cost. Unfortunately, I can no longer lend my name and reputation to the Company, nor support actions of the Board and Marlow Hernandez, which I believe are not in the best interest of stockholders. I have communicated my concerns to the Board and to Marlow Hernandez directly on numerous occasions, but they have largely been ignored. To be crystal clear, I do not believe Marlow should remain the Chairman & CEO of the Company. I believe that his continued tenure is harmful to the interests of stockholders and to Cano employees for all the reasons I have previously stated to you. I remain extremely troubled by the poor operating decisions and performance, by what I consider the opacity and obfuscation of information furnished to the Board, and by the inability to forecast the Company's financial performance over which Marlow and his management team have presided. These factors have caused the Company's stock price to be decimated, dropping over 90% from its debut, and the Company is now saddled with a crippling debt burden. The number and nature of related party transactions, together with what I consider poor governance (demonstrated by transactions such as MSP Recovery), is highly concerning to me as it should be to the rest of the Board. Instead of the Board calling the CEO to account, the majority of the Board has decided to continue to support the CEO and to continue to preside over the destruction of shareholder value. Over the past year and a half, some shareholders have called me to voice their concern over Marlow's stewardship and the Company's financial deterioration. I listened and conveyed their thoughts, which included these negative perceptions of our CEO, to the Board. The minority of the Board - myself, Lew Gold and Elliot Cooperstone - have tried to effectuate change, but as a minority our hands are limited by those who remain firmly aligned with Marlow for reasons I cannot understand. I have never witnessed such poor corporate governance at any company, let alone a public company, and I have been involved in at least nine and served as Chairman or CEO of six. As a steward of shareholder capital with fiduciary duties to stockholders, I cannot continue as a director under these circumstances. Lest there be any doubt, I am tendering my resignation because I have a fundamental disagreement with management as set forth in Item 502(a) of Form 8-K. Sincerely yours, Barry Sternlicht"

18:21 EDT Medical Properties Trust files lawsuit against short-seller Viceroy - Medical Properties Trust announced that it has filed a lawsuit in federal court against Viceroy Research, a short-selling firm that "has repeatedly published baseless allegations to drive down the company's stock price." "The lawsuit seeks permanent injunctive relief, disgorgement of ill-gotten gains, and compensatory and punitive damages from Viceroy and its members for defamation, civil conspiracy, tortious interference, private nuisance, and unjust enrichment," the company stated in a press release. MPT also issued a letter to shareholders, in which it states in part: "Since our founding, MPT's primary objective has been to profitably invest in hospital real estate and create attractive returns for our shareholders. We are proud that we have avoided distractions and maintained a relentless focus on that objective to deliver enduring results. These results include healthcare investments of more than $23 billion, the returns from which have generated more than $4.3 billion in cash dividends to you, our shareholders. Unfortunately, the chorus of false and intentionally deceptive claims from Viceroy Research and others who stand to benefit from declines in MPT's stock price has grown so loud that we can no longer sit by idly. Over the past few months, we have heard many of your suggestions to speak up and emphasize the facts, and today we have taken a decisive step in that respect by filing a lawsuit in federal court against Viceroy and its members... As our lawsuit makes clear, Viceroy's allegations are a litany of malicious falsehoods grounded in a distorted picture of our business. We encourage you to read the complaint filed today, which further corrects the record regarding many of these allegations and provides a better understanding of Viceroy's track record and intentions. We have tremendous opportunities ahead, with a highly liquid balance sheet with which to satisfy a well-laddered debt maturity schedule, relationships with the premier hospital operators in each of our markets and, as evidenced by our recent announcement of the pending sale of our Australian hospitals, a highly diversified portfolio of infrastructure-like assets that continue to attract new capital and profitable sales. We are confident in MPT's strategic positioning and continued ability to create value for shareholders."

18:19 EDT Novonix signs joint venture agreement with Taqat to produce battery materials - Novonix has agreed to establish an incorporated joint venture with Taqat in the Kingdom of Saudi Arabia to develop and produce anode materials for electric vehicle and energy storage system batteries in the Middle East and North Africa region. It is intended that the JV will undertake engineering for the facility in its first year with the target to begin facility construction in 2024. Novonix will contribute access on a royalty-free basis to its proprietary intellectual property to the JV for the production and sales of high-performance graphite anode in the Middle East and North Africa region. Taqat will hold a 60% equity stake in the JV vehicle and Novonix will hold a 40% stake with each party contributing their share of operating and capital costs for engineering and subsequent facility construction and operation. The joint venture is intended to utilize Novonix's battery technology and capability to develop a graphite anode materials facility with capacity of 30,000 tons per annum. The project is to be located in Saudi Arabia and is expected to secure ready access to precursor material as feedstock for critical battery materials and access to developing end-use markets for the manufacture and sale of EVs and ESS applications. Taqat has signed a Memorandum of Understanding with Rabigh Refinery & Petrochemical. Novonix will appoint the JV's CEO and COO and Taqat will appoint the JV's CFO. The JV will have a 5-person Board of Directors. Taqat has the right to appoint 3 directors to the Board and Novonix has the right to appoint 2 directors to the Board, reflecting the parties' respective equity interests in the JV. The parties must incorporate the JV vehicle, provide initial funding for a front-end engineering and design study and obtain merger control clearance from the Kingdom of Saudi Arabia's General Authority for Competition by 31 March 2024 in each case or the JV will terminate.

18:00 EDT Atai Life Sciences CEO Brand buys 70K shares of company stock - Atai Life Sciences CEO Florian Brand disclosed in a regulatory filing that he had purchased 70,000 shares of company stock at $1.48 per share on March 29, for a total transaction amount of $103,558.

17:44 EDT PGT Innovations adopts limited-duration shareholder rights plan - PGT Innovations has approved the adoption of a limited-duration shareholder rights plan in response to a likely accumulation of PGT shares by a strategic investor. The Rights Plan will reduce the likelihood that any entity, person or group gains control of the company through open market accumulation without paying all other shareholders an appropriate control premium or without providing the Board sufficient time to make informed judgments and take actions that it believes are in the best interests of shareholders. Under the Rights Plan, the rights will become exercisable if an entity, person or group acquires beneficial ownership of 10% or more of PGT's outstanding common stock in a transaction not approved by the Board. In the event that the rights become exercisable due to the triggering ownership threshold being crossed, each right will entitle its holder to purchase, at the then-current exercise price, additional shares of common stock having a then-current market value of twice the exercise price of the right. The Rights Plan is effective immediately and has a one-year duration, expiring on March 30, 2024.

17:13 EDT Virgin Orbit unable to secure funding, to cease operations, lay off 85% of staff - In an 8-K filing, the company states: "On March 30, 2023, the Company announced a workforce reduction of approximately 675 employees, constituting approximately 85% of the Company's workforce in order to reduce expenses in light of the Company's inability to secure meaningful funding. Those impacted are located in all areas of the Company. The Company estimates that it will incur aggregate charges of approximately $15 million, consisting primarily of (i) $8.8 million in severance payments and employee benefits costs, and (ii) $ 6.5 million in other costs primarily related to outplacement services and WARN Act exposure. The Company expects to recognize the majority of these charges in the first quarter of 2023. The Company expects that the reduction in force will be substantially complete by April 3, 2023."

17:10 EDT Globant expands global partnership with Google Cloud - Globant (GLOB) announced an expansion of its global collaboration with Google (GOOG) Cloud, which includes the creation of a new dedicated Google Cloud Studio. The new business unit will be focused on helping clients across Globant's verticals to adopt and maximize the benefits of Google Cloud. Globant and Google established their relationship more than 16 years ago.

16:53 EDT Y-mAbs Therapeutics jumps over 5% after Q4 results beat on top and bottom lines

16:42 EDT NovAliX teams with Galapagos in 5-year drug discovery collaboration - Galapagos and NovAliX announced a strategic collaboration in which Galapagos' research and discovery capabilities and exclusively related employees based in Romainville, France, will be transferred to NovAliX, a drug discovery-focused Contract Research Organization. The agreement follows Galapagos' renewed focus on its key therapeutic areas of oncology and immunology, and the strategic reorientation of the company into a fit-for-purpose research and development organization which aims to accelerate innovation, reduce risks and shorten drug development timelines. Under the terms of the agreement, NovAliX will acquire Galapagos' drug discovery and research activities conducted in Romainville, France. As a result of the acquisition Galapagos' employees in Romainville who are exclusively dedicated to the operation of these activities will be transferred to NovAliX who is dedicated to assuming all ongoing research and discovery activities in Romainville. In return, Galapagos is committed to utilizing the research capabilities and expertise of NovAliX through a five year-collaboration and within the context of the company's R&D portfolio. The financial impact is included in Galapagos' previously announced 2023 cash burn guidance in the range of EUR 380-420M. The transaction is subject to customary closing conditions and is anticipated to close in July 2023. "Last year, we announced our Forward, Faster strategy, and the strategic reorientation of our company into a fit-for-purpose R&D organization. In light of our renewed focus and our goal to safeguard the continued employment of our colleagues at our research site in Romainville, we are extremely pleased that we have come to an agreement with NovAliX," commented Paul Stoffels1, CEO and Chairman of Galapagos. "I would like to thank our teams and NovAliX for their trust and commitment throughout the past several months to make this happen. I am confident that our transferred colleagues together with the teams at NovAliX will thrive and that they will continue to contribute to the future success of Galapagos as part of this long-term collabor

16:33 EDT Marathon Oil to further develop Equatorial Guinea gas mega hub - Marathon Oil (MRO), through its affiliated company Marathon E.G. Holding Limited, announced it has signed a Heads of Agreement with the Republic of Equatorial Guinea and Noble Energy E.G. Ltd, a Chevron (CVX) company, to progress the next phases in the development of the Equatorial Guinea Regional Gas Mega Hub. More specifically, Phase II involves processing Alba Unit (MRO 64% interest) gas, from Jan. 1, 2024, under new contractual terms following the legacy Henry Hub-linked Alba sales and purchase agreement expiration at the end of this year. Phase II will materially increase MRO's exposure to global LNG pricing and is expected to improve the Company's E.G. earnings and cash flow significantly. Phase III of the GMH is expected to facilitate gas processing from the Aseng Field at Punta Europa facilities.

16:31 EDT DiamondHead Holdings, Great Southern Homes close business combination - DiamondHead Holdings (DHHC), a special purpose acquisition company, and Great Southern Homes jointly announced that they have closed their previously announced business combination. With the closing, DiamondHead Holdings Corp. has been renamed "United Homes Group, Inc.", and its common stock will begin trading on The Nasdaq Stock Market under the ticker symbol "UHG" on March 31, 2023.

16:29 EDT Juno Therapeutics' lisocabtagene maraleucel receives FDA orphan designation - According to a post on the FDA's website, Juno Therapeutics, a Bristol-Myers Squibb company, received orphan designation for its treatment of nodal marginal zone lymphoma, lisocabtagene maraleucel. Reference Link

16:25 EDT ResMed chief administrative officer, general counsel to retire - ResMed announced that David Pendarvis, chief administrative officer, global general counsel, and secretary, plans to retire, effective June 30. He will remain in a consulting role with ResMed through December 31.

16:17 EDT Shapeways to seek reverse stock split - Shapeways "intends to seek approval of a reverse stock split of its common stock at its Annual Meeting of Stockholders in June, which it would effect shortly thereafter. Details of the reverse stock split will be included in the Company's Proxy Statement for the Annual Meeting. The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on the New York Stock Exchange."

16:15 EDT Y-mAbs delivers DANYELZA to 48 centers up 12% from Q322 - As of December 31, Y-mAbs has delivered DANYELZA to 48 centers across the United States, corresponding to an increase of 12% in the number of centers since the third quarter of 2022. During the fourth quarter of 2022, approximately 53% of the vials sold in the United States were sold outside Memorial Sloan Kettering , an increase from the prior quarter as a result of the growth of new patients at institutions outside MSK outpacing MSK's growth of new patients.

16:08 EDT iStar reports final consolidation ratio in Safehold merger - iStar announced the final consolidation ratio that will be used in the reverse split of iStar common stock that will occur immediately prior to the effective time of the merger of iStar and Safehold. In the reverse stock split, each share of iStar common stock outstanding will be consolidated into 0.160 shares of iStar common stock. Immediately thereafter, Safe will merge with and into iStar, with iStar as the surviving corporation and operating under the name Safehold, and each outstanding share of Safe common stock will be converted into one share of common stock of New Safehold. The consolidated shares of iStar common stock will remain outstanding as common stock of New Safehold. iStar stockholders will receive cash in lieu of any fractional shares resulting from the reverse stock split.

16:07 EDT Spark Networks says continuing its strategic alternatives review

16:06 EDT Nkarta chief financial and business officer resigns - Nkarta announced that Nadir Mahmood has resigned his position as chief financial and business officer to serve as the chief executive officer of a private biotechnology company. Mahmood will remain with Nkarta until June 30 to ensure a transition. Nkarta remains on track to announce updated results from its ongoing clinical trial of NKX101 in the second quarter of 2023. Nkarta has initiated an external search for its next chief financial officer.

15:14 EDT VirnetX disagrees with Federal Circuit's decision, evaluating options - VirnetX Holding (VHC) announced that the United States Court of Appeals for the Federal Circuit issued a decision in appeals No. 2020-2271 and 2020-2272 involving certain claims of U.S. Patent Nos. 6,502,135 and 7,490,151. The Federal Circuit affirmed the decisions by the Patent Trial and Appeal Board in two inter partes review proceedings, which found claims 1, 3, 4, 7, 8, 10, and 12 of the '135 patent and claims 1, 2, 6-8, and 12-14 of the '151 patent to be unpatentable. "We are disappointed and disagree with the Federal Circuit's decisions in light of its past rulings on these same patents. We are evaluating all of our available options, including potentially seeking rehearing or certiorari review," said Kendall Larsen, VirnetX CEO and President. "The VirnetX announcement today of a special cash dividend of $1.00 per share remains intact regardless of litigation outcomes," the company added.

14:27 EDT Ford withdraws self-driving petition with NHTSA - In a letter made public on Thursday, Ford has withdrawn its petition to deploy a limited number of self-driving vehicles. According to the document, Ford "believes the road to fully autonomous vehicles, at scale, with a profitable business model, will be a long one. At this time, Ford has determined that is more prudent to focus on nearer-term L2/L3 technologies, which do not require an exemption. Hence, we would like to withdraw the subject petition for an exemption from further consideration." Reuters' David Shepardson has shared the letter via Twitter. Reference Link

14:02 EDT Wells Fargo fined $67.8M by Fed for 'inadequate oversight of sanctions risk' - The Federal Reserve Board announced that it has fined Wells Fargo $67.8M for the firm's "unsafe or unsound practices relating to historical inadequate oversight of sanctions compliance risks at its subsidiary bank, Wells Fargo Bank, N.A." "Wells Fargo & Co.'s deficient oversight enabled the bank to violate U.S. sanctions regulations by providing a trade finance platform to a foreign bank that used the platform to process approximately $532M in prohibited transactions between 2010 and 2015. The Board's action is being taken in conjunction with an action by the U.S. Department of the Treasury's Office of Foreign Assets Control, which is imposing a separate penalty on Wells Fargo Bank for these violations. The total penalty announced by both agencies is approximately $97.8M," the Fed stated.

13:59 EDT Biotricity CEO sees path to breakeven, profitability in next 18 months

13:55 EDT Biden urges regulators to tighten rules for large regional banks - The White House issued a fact sheet in which it states in part: "President Biden believes that resilient community and regional banks provide vital services to small businesses, workers, and families around the country. The Biden-Harris Administration has taken decisive action to ensure the stability of the banking system without putting taxpayer dollars at risk... The President believes that the weakening of common-sense bank safeguards and supervision during the Trump Administration for large regional banks should be reversed in order to strengthen the banking system and protect American jobs and small businesses. Specifically, the President urges the federal banking agencies, in consultation with the Treasury Department, to consider a set of reforms that will reduce the risk of future banking crises, including reinstating rules that were rolled back in the previous Administration for banks with assets between $100 and $250 billion; Taking steps to once again ensure strong supervision; Expanding long-term debt requirements to a broader range of banks; Ensuring that the costs of replenishing the Deposit Insurance Fund after these recent bank failures are not borne by community banks... Each of these items can be accomplished under existing law, and they build upon regulatory reforms already on this Administration's agenda, like completion of the executive compensation rule for bank executives authorized under Section 956 of the Dodd-Frank Act." Reference Link

12:02 EDT Presto Automation appoints Dan Mosher president, Xavier Casanova COO - Presto Automation announced the promotion of Dan Mosher to president and Xavier Casanova to chief operating officer, effective immediately. Mosher has served as the Company's chief revenue officer since he joined Presto in March 2021. He will continue to focus on the customer-facing and commercial sides of Presto's business and work with Gupta to implement the Company's critical strategic and financial initiatives. Casanova will head operations for Presto and continue to drive innovation and streamline operations across engineering, product management, and other support functions.

12:00 EDT Annovis Bio falls -11.3% - Annovis Bio is down -11.3%, or -$2.49 to $19.61.

12:00 EDT Metropolitan Bank falls -21.8% - Metropolitan Bank is down -21.8%, or -$7.65 to $27.37.

12:00 EDT Emergent BioSolutions rises 14.4% - Emergent BioSolutions is up 14.4%, or $1.35 to $10.70.

11:46 EDT EVgo: Buy American government requirements to delay some projects near-term - EVgo still sees rapid growth in EV charger deployment, the company said on its Q4 earnings conference call.

11:38 EDT Locafy Ltd trading halted, volatility trading pause

11:30 EDT Spirit Airlines to hire over 4,000 new team members in 2023 - Spirit Airlines announced plans to hire more than 4,000 new Team Members in 2023 as the airline adds new planes and destinations to its growing network. The new hires will include Pilots, Flight Attendants, Aviation Maintenance Technicians and other support center roles. Plus, Spirit is growing in new and existing cities, with positions available with Spirit and business partners at airport stations across the network.

10:33 EDT Under Armour confirms long-term partnership with Stephen Curry - Under Armour announced that it is strengthening its partnership with Golden State Warriors point guard and four-time NBA Champion Stephen Curry. The company said, "The enhanced partnership is designed to capture market share, fuel business growth and create new business opportunities on a global basis. This next chapter of the partnership will build upon the success and accomplishments from the past decade to continue driving product solutions and innovation, impacting communities across the globe, and growing Under Armour and Curry Brand together." Stephen's new role as President of Curry Brand will enhance his ability to drive athlete insights, product development, and strategic business and marketing endeavors. In this next phase of the partnership, Under Armour and Stephen will elevate this commitment across categories-from basketball to golf, women, youth, and sportstyle-delivering product solutions that help athletes perform at the highest level. Stephen will also assume a broad advisory role where his sphere of impact will strengthen brand love, recruitment, and present opportunities across categories to reach and expand Under Armour's athlete roster.

10:17 EDT CBRE IM, Accelerate launch partnership to acquire infrastructure ground leases - Accelerate Investment Partners and CBRE Investment Management have launched Accelerate Infrastructure Opportunities, a new strategy to invest in digital and renewable real property interests across North America. Accelerate's infrastructure strategy acquires, owns and manages investments in ground leases and land under critical infrastructure assets that generate long-term, sustainable cash flow, such as cellular infrastructure, billboards and renewable assets, including wind, solar, storage and EV charging projects.

10:10 EDT Curo Group says will continue to monitor Canada's proposed 2023 budget - CURO Group Holdings responds to the federal government of Canada's proposed 2023 Budget. On March 28, 2023, the federal government of Canada announced, in connection with its proposed federal budget, its intent to introduce legislation to reduce the maximum allowable rate of interest under its criminal code from an annual percentage rate of 47% to an APR of 35%. In connection with the Proposal's announcement, CURO issued the following statement: "We are proud of the work we do to provide timely, transparent, affordable and convenient financial solutions to customers who are underserved by mainstream banks, credit card companies and other traditional financial services companies. As with any proposals or plans by governmental agencies, there will be a process undertaken before any final rule or law is adopted related to the Proposal and any such final rule or law may differ materially from the Proposal. During this process, we look forward to working with the federal government of Canada and other industry participants to demonstrate how our customers will be harmed by the Proposal, particularly at a time when they need a financial service like ours more than ever. We believe it is too early to determine the long-term impact of the Proposal on the Company's businesses considering no draft legislation or legislative commentary is available. Accordingly, we will continue to monitor the Proposal and assess its implications as more is known and we will continue to manage our business to serve our customers and maintain an appropriate level of risk adjusted returns for the Company."

10:04 EDT Sotheby's International Realty opens first affiliated office in Saudi Arabia - Sotheby's International Realty announced the opening of Saudi Arabia Sotheby's International Realty, signifying the brand's seventh affiliated office in the Middle East and its 227th office in the EMEIA region. The company is headquartered in the Al Faisaliah Tower in the city of Riyadh and will service the entire country.

10:03 EDT JD.com intends to spin-off JD Property, JD Industrials - JD.com announced that it intends to spin-off JD Property and JD Industrials by way of separate listings on the Hong Kong Stock Exchange. The company submitted spin-off proposals to the Hong Kong Stock Exchange and the exchange confirmed JD may proceed with the proposed spin-offs. Upon completion of the spin-offs, the company will continue to indirectly hold more than 50% of the shareholdings in JD Property and JD Industrials, and therefore both will remain as a subsidiary of the company. Shares of JD.com are up 7% to $44.09 following the announcement.

10:00 EDT Dorian LPG falls -4.4% - Dorian LPG is down -4.4%, or -92c to $19.66.

10:00 EDT Franklin Covey falls -14.7% - Franklin Covey is down -14.7%, or -$6.50 to $37.73.

10:00 EDT Sprinklr rises 13.7% - Sprinklr is up 13.7%, or $1.49 to $12.37.

09:56 EDT Benesch selects Intapp's DealCloud as client relationship management platform - Intapp announced that Benesch, Friedlander, Coplan & Aronoff has selected DealCloud as its client relationship management platform

09:50 EDT Iconiq Hdg Corp trading halted, volatility trading pause

09:47 EDT Dorian LPG falls -3.4% - Dorian LPG is down -3.4%, or -69c to $19.89.

09:47 EDT Planet Labs rises 12.4% - Planet Labs is up 12.4%, or 44c to $3.98.

09:47 EDT Sprinklr rises 19.5% - Sprinklr is up 19.5%, or $2.12 to $13.00.

09:35 EDT Bed Bath & Beyond launches new ATM offering, terminates previous warrants - Bed Bath & Beyond announced that concurrent with a new, At-The-Market, or "ATM," offering program launched earlier today, the company has also entered into a common stock purchase agreement and a registration rights agreement with B. Riley Principal Capital II to provide additional capital to the company. Simultaneously, the company is terminating its previous public equity offering and all outstanding warrants for Series A Convertible Preferred Stock associated with that offering. "The company intends to file a registration statement on Form S-1 with respect to the Committed Equity Facility, upon the effectiveness of which the company would be permitted to begin selling additional securities pursuant to its terms," Bed Bath stated. Sue Gove, President & CEO of Bed Bath & Beyond Inc. said, "The actions we've taken have enabled us to create the necessary financial runway to begin restoring our iconic Bed Bath & Beyond and buybuy BABY businesses. We have raised $360 million of equity capital since the beginning of February, cured our default under our credit agreement, repaid material amounts of our ABL facility, completed our interest payment for our Senior Notes, all while jumpstarting our turnaround plans. The customer experience remains our top priority and we are making meaningful progress to improve our business and calibrate to customer demand. In addition to leveraging our recent capital to reinvest in high demand inventory, we are also developing a third-party consignment program that will allow us to fortify our product assortments by expanding merchandise availability from key supplier partners. We are on pace to achieve our target of 360 top-performing Bed Bath & Beyond stores by the end of April, in addition to our existing 120 buybuy BABY stores. In conjunction with our online business, these productive stores are pivotal to our omni-channel strategy and future profitability. As demonstrated by our plans for additional equity capital, our work remains focused on creating operational and financial avenues for further progress. We believe today's launch of the ATM Program will expand the reach of our equity program, and accelerate the return of our nationally recognized Bed Bath & Beyond and buybuy BABY brands back to prominence."

09:28 EDT MaxCyte director buys $345.5K in common stock - In a regulatory filing, MaxCyte disclosed that its director Richard Douglas bought 80K shares of common stock on March 29th in a total transaction size of $345.5K. Shares are up 4.8% at $4.62 in pre-market trading.

09:22 EDT Volcon launches Grunt EVO, Runt LT off-road motorcycles - Volcon has launched the new Grunt EVO and the Runt LT. The EVO is the latest edition of the Company's original all electric off-road motorcycle using Volcon's Exo-Arch frame and fat-tired design, now affectionately called the Grunt Founders Edition internally. The EVO streamlines design, comfort, and style while offering improvements based on Grunt consumer feedback.

09:17 EDT Illumina urges shareholders to withhold votes for Icahn Group director nominees - Illumina filed its preliminary proxy statement with the SEC. The company said, in part, "The activist investor Carl Icahn has nominated three of his associates to stand for election to the Board of Directors at Illumina's 2023 Annual Meeting of Shareholders. Illumina recommends shareholders vote in favor of the company's Board of Directors and withhold votes for the three Icahn Group director nominees. Carl Icahn's involvement with Illumina risks the long-term success of the company, and his director nominees bring no relevant skills to the Board of Directors."

09:11 EDT PPL Corp. unit gains regulatory approval for $290M of network improvements - PPL Corporation announced that the Rhode Island Public Utilities Commission has approved $290M to improve Rhode Island's electric and gas networks in connection with the latest Infrastructure, Safety, and Reliability plans proposed by PPL subsidiary Rhode Island Energy. The ISR plans are submitted annually and outline proposed capital investments to strengthen the state's electric and gas infrastructure. In addition, the electric ISR plan includes related operating costs for vegetation management, system inspection and other work related to maintaining the safety and reliability of the electric distribution system. The approved plans address proposed spending from April 1, 2023, to March 31, 2024.

09:08 EDT Mangoceuticals retains ShareIntel to combat illegal short selling activities - Mangoceuticals announced that it has retained Shareholder Intelligence Services for a 12-month, full-service agreement to review the trading of the Company's common stock to track, identify and monitor for potential illegal short selling activities and deploy solutions to help combat any such activities. ShareIntel aggregates and analyzes shareholder trading data through its DRIL-Down process, a compliance driven Software-as-a-Service "SaaS" platform that examines equity flows and reveals suspicious, aberrant, and/or unusual trading activity. The tool aims to help management to identify, interpret and communicate shareholder and broker-dealer movement to the market. The Company is concerned that it may have been the target of a market manipulation scheme involving illegal short selling based on the recent trading pattern of the stock. The Company is committed to taking all necessary actions to protect the interests of its shareholders and will continue to work with ShareIntel and other partners to combat potential manipulative and egregious illegal short selling and trading activities to help ensure fair market conditions.

09:05 EDT HUMBL announces marketing partnership with WNFC - HUMBL announced a marketing partnership with the Women's National Football Conference, WNFC. HUMBL will become the official "Blue Zone" sponsors of the league for the 2023 season. Turning the traditional Red Zone into the HUMBL "BLUE ZONE" with signage and commentator mentions. HUMBL will also activate its sponsorship across the HUMBL platform through the HUMBL digital wallet, search engine, verified social media and authenticated, signed merchandise. "We believe that women's sports are a tremendous growth opportunity for consumer technologies and direct brand-to-fan engagement. HUMBL is proud to be aligned with the WNFC and we look forward to seeing their athletes, teams, fans and content served in new ways across our the HUMBL platform," said Brian Foote, CEO of HUMBL.

09:03 EDT Entergy, RWE partner to analyze Gulf of Mexico offshore wind market - RWE and Entergy have agreed on a partnership to analyze the Gulf of Mexico offshore wind market. The companies signed a Memorandum of Understanding to jointly evaluate the delivery of clean energy from offshore wind to industrial customers in Texas and Louisiana. Under this MOU, RWE and Entergy agree to assess five key areas to define an optimal route-to-market including: market demand for carbon-free energy for customers of Entergy Louisiana, Entergy New Orleans and Entergy Texas; resource economics; transmission analysis to ensure reliability; economic impacts extending to direct and indirect job creation; and curricula to prepare the workforce of the future.

09:01 EDT GCM Grosvenor opens office in Australia - GCM Grosvenor announced that it is opening an office in Australia to serve and grow its client base in the region. The office will be located in Sydney and led by Andy Lukas. Andy has over 20 years of experience managing client relationships, most recently at HSBC where he provided multi-strategy solutions for institutional clients. At GCM Grosvenor, Andy will be dedicated to delivering the firm's alternative investment solutions to investors in Australia and New Zealand. With the new office and hire, GCM Grosvenor builds on its focus to expand global access to the breadth of the firm's alternatives solutions. In recent years, the firm also made senior hires and opened offices in Toronto, Canada and Frankfurt, Germany.

09:01 EDT Hershey announces NCAA partnership extension - The Hershey Company announced a six-year extension with CBS Sports, Warner Bros. Discovery Sports and the NCAA as the "Official Confectionary Partner." In addition to Hershey's number #1 brand, Reese's, the renewed deal will include Hershey's growing salty snack brands, Dot's Homestyle Pretzels and SkinnyPop Popcorn as the "Official Pretzel and Popcorn Partner" of the NCAA.

08:58 EDT RenovoRx to present RenovoGem data at AACR - RenovoRx announced that it will present detailed, open label, planned Phase III interim data analysis of its innovative RenovoGem therapy for pancreatic cancer patients at the American Association for Cancer Research, or AACR. The interim analysis shows a six-month median overall survival benefit for patients. That is nearly a 60% improvement versus the study control arm and current standard of care: intravenous, or IV, administration of gemcitabine and nab-paclitaxel for locally advanced pancreatic cancer, or LAPC. RenovoGem patients also had greater than 65% reduction in adverse events. These can include nausea, fatigue, and a decline in white blood cells.

08:53 EDT MSG Entertainment spikes over 3% higher after announcing spin-off -

08:49 EDT BriaCell intends to spin-out certain pre-clinical assets into 'SpinCo' entity - BriaCell Therapeutics announced that its Board of Directors has unanimously approved a potential reorganization that would result in the spin-out of certain pre-clinical pipeline assets of the Company, specifically Bria-TILsRx, and PKCdelta inhibitors for multiple indications including cancer to an unlisted corporation to own the SpinCo Assets. On closing of the Transaction, it is anticipated that the SpinCo Assets will be majority-owned, controlled, and governed by BriaCell and owned by BriaCell shareholders of record who will receive SpinCo Shares as defined herein. On closing of the Transaction, it is expected that each share of BriaCell will be exchanged for one new share of the post-Transaction Company and one common share of SpinCo. SpinCo Shares issued to BriaCell shareholders will comprise 33.33% ownership of SpinCo Shares upon closing of the Transaction. BriaCell shareholders who receive SpinCo Shares will ultimately own shares in both companies: BriaCell, which will continue with its mission to develop targeted immunotherapies for cancer, and SpinCo, which will focus on the development of the SpinCo Assets. SpinCo may seek funding subsequent to the closing of the Transaction and will intend to use the majority of the proceeds to advance the development of the SpinCo Assets. It is anticipated that the SpinCo Shares will be issued to BriaCell shareholders by way of a plan of arrangement under the Business Corporations Act. BriaCell will retain SpinCo Shares representing 66.67% ownership of SpinCo. It is intended that SpinCo will be managed by Dr. William V. Williams, as President and CEO, and Mr. Gadi Levin, as CFO. SpinCo's board of directors will consist of, BriaCell's current board of directors' members including Dr. William V. Williams, Mr. Martin E. Schmieg, and Dr. Jane A. Gross. Following the Transaction, BriaCell will remain listed on both the NASDAQ Stock Market and Toronto Stock Exchange, and SpinCo will become an unlisted reporting issuer in Canada. The Transaction will be implemented by way of a court approved plan of arrangement under the Act. The Transaction will require the approval of: 66.67% of the votes cast by the holders of BriaCell's shares; and, if required, a simple majority of the votes cast by holders of BriaCell's shares after excluding votes from certain shareholders as required under Multinational Instrument 61-101 - Protection of Minority Security Holders in Special Transactions, at a special meeting of BriaCell's shareholders to be held to consider the Transaction. In addition to shareholder approval, the Transaction is also subject to the receipt of court approval and other customary closing conditions for transactions of this nature.

08:48 EDT Abercrombie & Fitch launches co-designed collection with Tia Booth - Abercrombie & Fitch, a division of Abercrombie & Fitch, announced its first ever co-designed collaboration with television personality, Tia Booth. The collection, which launches March 30 online and in stores for North American and European customers, drops just in time for the upcoming travel and getaway season. "We feel so fortunate to bring our longtime friendship with Tia to life in such a beautiful, co-designed collection," said Carey Krug, Chief Marketing Officer at Abercrombie & Fitch Co. "Abercrombie aims to make every day feel as exceptional as the start of a long weekend and, through our collaboration with Tia, we've been able to combine that ethos with the joy, optimism and fun that she brings to her community each and every day."

08:47 EDT Hepion Pharmaceuticals expands SAB with appointments of four new members - Hepion Pharmaceuticals announces the addition of four new internationally recognized thought leaders to its Scientific Advisory Board, SAB, effective immediately. These new members, who bring decades of liver disease research and drug development experience to the Hepion SAB, include: Rohit Loomba, MD; Vlad Ratziu, MD; Yury V. Popov, MD, PhD; Nikolai Naoumov, MD, PhD. The new Hepion SAB members join existing members Stephen Harrison, MD (Chair) and Philippe Gallay, PhD.

08:46 EDT AIM ImmunoTech appoints Bryan to board of directors - AIM ImmunoTech announced Nancy Bryan as the newest member of its Board of Directors. She has also been named to a number of committees. Bryan is an established leader with more than 25 years of experience in the life sciences industry. She has served on executive leadership teams and played key roles in companies' successes, including marketing, sales, business development, financing and communications. Bryan is the current President and CEO of BioFlorida.

08:43 EDT FG Group says Strong Technical Services delivered tech to Prytania Theatre - FG Group Holdings announced that Strong Technical Services has delivered the latest in cinema projection and sound technology to the Prytania Theatre, a historic landmark in New Orleans, with the installation of 4K laser digital projection and Dolby Atmos immersive audio powered by Meyer Sound cinema series loudspeakers. Travis Henning, Director of Sales for Strong Technical Services, commented, "The Prytania Theatre is deeply rooted in both the city of New Orleans and vintage cinema, having operated as a neighborhood movie house since it first opened its doors in 1914. We are pleased to assist the Prytania in these technology upgrades to provide moviegoers with the very best cinematic experience powered by Meyer Sound, while also maintaining the important history and personality that so many people have appreciated over the theater's 100-plus years of continuous operation."

08:42 EDT Star Equity announces update to its director nominations at Servotronics - Star Equity Fund (STRR) is an investment fund focused on unlocking shareholder value and improving corporate governance at its portfolio companies. Star Equity Fund owns 5.4% of the common stock of Servotronics (SVT) and, for the benefit of all SVT stockholders, announced that it will be proceeding with the nomination of two qualified candidates for election to the Company's board of directors at the Company's 2023 annual meeting of shareholders. As we mentioned in our press release on February 14, 2023, STar has concluded the only way to improve corporate governance and maximize shareholder value at SVT is to change the composition of the incumbent Board. It are seeking to replace Edward Cosgrove and Christopher Marks, the longest tenured Board members, who have overseen a period of value destruction, poor financial and operating performance, and bad corporate governance. As a whole, we believe the incumbent Board lacks the necessary experience and expertise to change the trajectory at SVT. Mark Pomeroy spent 20 years working for General Electric's (GE) Aircraft Engine division where he acted as both a Master Black Belt staff engineer and Manager of Fleet Operations and Engine Overhaul Customer Satisfaction. Richard Coleman currently serves as Chief Executive Officer for Star Equity Holdings, a diversified holding company, and has served on the board of directors since April 2022.

08:41 EDT DraftKings co-founders Robins, Kalish sell about $10M in common stock - In regulatory filings last night, DraftKings disclosed that its co-founder Jason Robins sold 300K shares of common stock for $5.32M and Matt Kalish sold 269K shares of common stock for $4.77M on March 27th.

08:38 EDT Medavail postpones reporting Q4, FY22 results - MedAvail Holdings is postponing its scheduled earnings release and conference call for the fourth quarter and full-year ended December 31, 2022 previously scheduled for today. The Company requires additional time to complete the preparation and corresponding audit of its consolidated condensed financial statements as of and for the year ended December 31, 2022. In connection with the Company's divestiture of its pharmacy services business, the Company and its auditors need more time to complete their year-end procedures and reporting. The Company plans to file a timely Notification Late Filing on Form 12b-25 to extend the filing deadline for the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022. The Company will announce the date and time of its scheduled fourth quarter and full-year ended December 31, 2022 financial results and conference call in a future press release.

08:38 EDT Genasys expands critical communications coverage in San Diego County - Genasys (GNSS) announced a new multi-year Zonehaven evacuation management software-as-a-service contract with San Diego County, California. "San Diego joins Riverside County, Marin County, Alameda County, and other California jurisdictions deploying the full Genasys Protect platform to deliver multichannel public safety alerts, evacuation notifications, and life safety information to residents and visitors," said Richard Danforth, Chief Executive Officer, Genasys, Inc. "Genasys Protect is the first and only unified platform that provides comprehensive emergency management and multichannel communications solutions before, during, and after disasters and other critical events. The Company also announced Brian Alger as Senior Vice President of Investor Relations and Corporate Development. Alger previously served as Senior Vice President, Corporate Development & Investor Relations, for Veritone (VERI) from 2019 - 2023.

08:36 EDT Predictive Oncology announces collaboration with Integra Therapeutics - Predictive Oncology announces it is partnering with Integra Therapeutics, a company focused on engineering the next generation of gene writing tools to cure diseases. The collaboration was created to pursue a novel method to enhance Integra Therapeutics' ability to use gene editing for future cancer therapies. "Our novel formulation technology and protein expression experience positions Predictive Oncology to help advance Integra's goals," said Larry DeLucas, Senior Vice President of Biologics, Predictive Oncology. Integra Therapeutics selected Predictive Oncology because of the company's protein expression experience and unique ability to optimize solubility and physical stability for expressed proteins. Predictive Oncology uses a proprietary automated technology, called high-throughput self-interaction chromatography, to rapidly and accurately measure biomolecular interactions that assist pharmaceutical and biotech companies in drug development.

08:35 EDT Atlis Motor Vehicles adds Jasthi as VP of Software - Atlis Motor Vehicles announced the addition of Srinivas Jasthi to its leadership team, further bolstering the strength and effectiveness of AMV management as they focus on product delivery and driving value for shareholders. As Vice President, VP, of Software, Jasthi will oversee development of future integrated and connected cloud service systems, as well as in-house services, mobile, and cloud payment services for Atlis Energy products.

08:35 EDT Star Equity announces update to its director nominations at Servotronics - Star Equity Fund is an investment fund focused on unlocking shareholder value and improving corporate governance at its portfolio companies. Star Equity Fund owns 5.4% of the common stock of Servotronics (SVT) and, for the benefit of all SVT stockholders, announced that it will be proceeding with the nomination of two qualified candidates for election to the Company's board of directors at the Company's 2023 annual meeting of shareholders. As we mentioned in our press release on February 14, 2023, STar has concluded the only way to improve corporate governance and maximize shareholder value at SVT is to change the composition of the incumbent Board. It are seeking to replace Edward Cosgrove and Christopher Marks, the longest tenured Board members, who have overseen a period of value destruction, poor financial and operating performance, and bad corporate governance. As a whole, we believe the incumbent Board lacks the necessary experience and expertise to change the trajectory at SVT. Mark Pomeroy spent 20 years working for General Electric's (GE) Aircraft Engine division where he acted as both a Master Black Belt staff engineer and Manager of Fleet Operations and Engine Overhaul Customer Satisfaction. Richard Coleman currently serves as Chief Executive Officer for Star Equity Holdings (STRR), a diversified holding company, and has served on the board of directors since April 2022.

08:34 EDT VirnetX enters cooperation agreement with Bradley Radoff and Michael Torok - In conjunction with the special cash dividend, VirnetX (VHC) entered into a cooperation agreement with Bradley Radoff and Michael Torok and certain of their respective affiliates, who collectively own approximately 6.6% of VirnetX's common stock. As part of the agreement, VirnetX committed to promptly distribute to shareholders 80% of future proceeds, if any, and net of related legal costs, licensing costs and taxes, that it receives from its current litigation with Apple (AAPL). During 2021, Apple appealed a 2020 U.S. Federal District Court jury verdict that awarded VirnetX over $500M in damages. Oral arguments for this appeal were heard by the U.S. Court of Appeals for the Federal Circuit in September 2022. VirnetX has also agreed to further strengthen its Board of Directors through the selection and addition of another independent director within the next 12 months who will help improve diversity in the boardroom.

08:31 EDT VirnetX announces special cash dividend of $1.00 per common share - The dividend will be paid on or about April 17 to shareholders of record on April 10.

08:28 EDT Amesite, NAFEO Alliance expand to twelve member universities - Amesite announces today that new member universities have joined their collaborative alliance with the National Association for Equal Opportunity in Higher Education, the membership and advocacy association of all Historically Black Colleges and Universities and Predominantly Black Institutions.

08:24 EDT Smith-Midland Corp announces delayed filing of 2022 Form 10-K - Smith-Midland Corporation announced that it will file a Form 12b-25 with the Securities and Exchange Commission to provide notice of the late filing of its Annual Report on Form 10-K for the year ended December 31, 2022. The company expects to file its Form 10-K on or before April 15, 2023. The extension is needed to gather additional information to complete auditing procedures of the Company's financial statements for the year ended December 31, 2022.

08:22 EDT XS Financial appoints Justin Vuong as CFO - XS Financial announced that Justin Vuong has been named CFO effective June 1st, 2023. Mr. Vuong succeeds XS Financials' current CFO Stephen Christoffersen, who will remain active as a member of the Company's Board of Directors, Investment Committee, and has been appointed as Audit Chair. Vuong has served as Senior Vice President of Corporate Development of XS Financial since 2018 and has been instrumental in the overall growth of XS Financial since its inception.

08:21 EDT OverActive Media signs first all-female esports team - OverActive Media announced its entry into VALORANT Game Changers. OverActive signed a fully female Spanish roster that will compete as MAD Lions Laure. MAD Lions Laure joins other prominent organizations in the scene, including Team Liquid, Natus Vincere, FaZe Clan and G2 Esports. The MAD Lions Laure roster consists of Monica "moniovess" Oves Silva, Laia "MissLaia" Miralles Brull, Alessia "Alessia" Crisafo Norte, Lucia "Nahashi" Mata Vergara, Nicole "Nidxvilco" Dobrovolskyy Shved and Coach Adrian "Jedry" Garcia Saiz.

08:19 EDT Power Solutions announces extension to credit agreement - Power Solutions International amended its $130 million uncommitted senior secured revolving credit agreement with Standard Chartered Bank as administrative agent, and the lenders party thereto from time to time. The Third Amended and Restated Credit Agreement extends the maturity date of loans outstanding under its previous credit facility to the earlier of March 22, 2024 or the demand of Standard Chartered. The Third Amended and Restated Credit Agreement is fully drawn as of the date of this release. The Third Amended and Restated Credit Agreement is subject to customary events of default and covenants, including minimum consolidated EBITDA and Consolidated Interest Coverage Ratio covenants for the second and third quarters of 2023. Borrowings under the Third Amended and Restated Credit Agreement will incur interest at either the alternate base rate or the Secured Overnight Financing Rate plus 3.35% per annum. The obligations under the Third Amended and Restated Credit Agreement are unconditionally guaranteed, on a joint and several basis, by certain wholly-owned, existing and subsequently acquired or formed direct and indirect domestic subsidiaries of the Company, subject to customary exceptions. The obligations under the Third Amended and Restated Credit Agreement are secured by substantially all assets of the Company and the Company's wholly-owned subsidiaries In connection with the Third Amended and Restated Credit Agreement, on March 24, 2023, the Company also amended two of its four separate shareholder's loan agreements with its majority stockholder, Weichai America, to among other things, extend the maturities thereof. The first shareholder's loan agreement, which was set to mature on April 24, 2023, provides the Company with a $130.0 million subordinated loan under which Weichai is obligated to advance funds solely for purposes of repaying outstanding borrowings under the Third Amended and Restated Credit Agreement if the Company is unable to pay such borrowings. The fourth shareholder's loan agreement, which was set to mature on March 31, 2023, provides the Company with a $30 million subordinated loan at the discretion of Weichai. The maturity of the First Shareholder's Loan Agreement was extended to April 24, 2024 and the maturity of the Fourth Shareholder's Loan Agreement was extended to March 31, 2024. Borrowings under both agreements will bear interest at an annual rate equal to SOFR plus 4.05% per annum. Further, if the applicable term SOFR is negative, the interest rate per annum shall be deemed as 4.05% per annum. If the interest rate for any loan is lower than Weichai's borrowing cost, the interest rate for such loan shall be equal to Weichai's borrowing cost plus 1%. Both of the agreements are subject to customary events of default and covenants. The Company has covenanted to secure any amounts borrowed under either of the agreements upon payment in full of all amounts outstanding under the Third Amended and Restated Credit Agreement. As of March 24, 2023, there were no borrowings under the First Shareholder's Loan Agreement and approximately $4.8 million drawn under the Fourth Shareholder's Loan Agreement. The Company is also party to two other loan agreements with Weichai, including the $25 million second amended and restated shareholder's loan agreement and the $50 million first amended and restated shareholder's loan agreement. The Second Shareholder's Loan Agreement will mature on May 20, 2023 and the Third Shareholder's Loan Agreement will mature on November 30, 2023. The Company intends to work with Weichai to extend both the Second Shareholder's Loan Agreement and the Third Shareholder's Loan Agreement as the maturity date approaches. As of March 24, 2023, both the Second Shareholder's Loan Agreement and the Third Shareholder's Loan Agreement have been fully drawn.

08:17 EDT Sight Sciences defeats invalidity challenges filed by Alcon, Ivantis - Sight Sciences (SGHT) reported that it defeated all four patent invalidity challenges filed by Alcon (ALC) and Ivantis in the United States Patent and Trademark Office. Patent Infringement Litigation Over Hydrus Microstent: On September 16, 2021, the Company filed suit in the U.S. District Court for the District of Delaware alleging that Ivantis, Inc. infringes U.S. Patent Nos. 8,287,482, 9,370,443, 9,486,361, and 10,314,742 by making, using, selling, and offering for sale the Hydrus Microstent. The Company's complaint seeks money damages and injunctive relief. On August 1, 2022, the Company filed an amended complaint adding Alcon Inc., Alcon Vision, LLC and Alcon Research, LLC as defendants and added allegations of infringement of U.S. Patent No. 11,389,328. Ivantis and Alcon responded to the Company's lawsuit by filing petitions for inter partes review with the U.S. Patent Office seeking the invalidation of U.S. Patent Nos. 8,287,482, 9,370,443, 9,486,361, and 10,314,742. On March 21st, 22nd, and 27th, 2023, the U.S. Patent Office denied each of Alcon's and Ivantis's petitions, concluding in each case that commencing a review proceeding to evaluate their invalidity challenges was unwarranted. The Patent Office found that the same or substantially the same prior art previously had been presented to the Patent Office during examination of the Company's patents, and Alcon and Ivantis had not demonstrated that the Patent Examiner materially erred when considering the prior art. Records of the inter partes review proceedings are publicly available at the Patent Office website. Denials of Alcon's and Ivantis's petitions are not appealable. A five-day jury trial regarding Sight Sciences' patent infringement claims against Alcon and Ivantis is scheduled to commence in Wilmington, Delaware on April 8, 2024.

08:15 EDT Skillful Craftsman establishes new subsidiary in Singapore - Skillful Craftsman Education Technology announced the establishment of a wholly-owned subsidiary in Singapore, LE FIRST SKILLAND, LFS, to facilitate the Company's global business development of vocational education. Through the establishment of LFS, the Company expects to integrate Singapore's vocational skills standards into the development of skilled workers in vast labor-intensive countries, to meet the urgent demand for skilled workers in developed countries with aging populations. Meanwhile, LFS is also expected to advance vocational education and increase the income of people in underdeveloped areas, thereby fulfilling the Company's mission to promote social development.

08:14 EDT InnovAge appoints Patty Fontneau to board of directors - InnovAge Holding announced the appointment of Patty Fontneau to its Board of Directors, effective immediately. Fontneau joins InnovAge's Board as Pavithra Mahesh of Apax Partners and Caroline Dechert of Welsh, Carson, Anderson & Stowe simultaneously step down from their positions with the Board. These changes maintain the participation of the investment firms while adding additional independent and community representation on the Board. Fontneau is currently the CEO of Reach Out and Read Colorado, an organization that works with health care providers to provide age and language appropriate books to new parents, and to educate them on the importance of reading to their children.

08:13 EDT Achieve Life Sciences announces board refresh - Achieve Life Sciences announced changes to the Company's Board of Directors to continue to support the future direction of the Company. As provided in the previously reported Cooperation Agreement, as amended, between the Company and certain of its shareholders, Mr. Stuart Duty, Mr. Thomas King, and Mr. Tom Sellig have been appointed to the Board of Directors and will be nominated for election at the Company's Annual Meeting of Stockholders to be held in June 2023. Additionally, each of Mr. Donald Joseph, Dr. Martin Mattingly, and Mr. Jay Moyes will not be nominated for re-election at the Annual Meeting.

08:12 EDT AquaBounty director Richard Clothier to retire - AquaBounty Technologies announced that Richard Clothier will retire from the AquaBounty Board of Directors and will not stand for reelection at the Company's Annual Shareholder Meeting on May 25, 2023.

08:09 EDT Apollomics announces closing of business combination, listing on Nasdaq - Apollomics (APLM) announced the completion of its business combination with Maxpro Capital Acquisition Corp. (JMAC). Apollomics' Class A ordinary shares and public warrants are expected to commence trading today, March 30, 2023, on the Nasdaq Capital Market under the symbols "APLM" and "APLMW," respectively. The Business Combination, which was approved by Maxpro's shareholders on March 20, 2023, along with a $23.65 million private investment in public equity financing raised in connection with the Business Combination, provides access to capital that is expected to enable the Company to advance its pipeline of drug candidates. Apollomics will continue to be led by Dr. Yu, a serial entrepreneur and pharmaceutical researcher with more than 300 patents, as its Chief Executive Officer and Chairman of the Board of Directors. The Apollomics executive leadership team will also consist of: Dr. Sanjeev Redkar, Ph.D., MBA, Apollomics' Co-Founder, who will continue to serve as President and will serve as a Director; Dr. Jane Wang, Ph.D., who will continue to serve as Chief Scientific Officer; and Dr. Peony Yu, MD, who will continue to serve as Chief Medical Officer. In addition to Dr. Yu and Dr. Redkar, Apollomics' Board of Directors will also consist of: Dr. Jonathan Wang, Ph.D., MBA; Dr. Kenneth C. Carter, Ph.D.; Dr. Hong-Jung Chen, Ph.D.; Wendy Hayes, MBA; and Glenn S. Vraniak, MBA.

08:08 EDT Candel Therapeutics expects cash to fund operating plan into 2Q24 - Cash and cash equivalents as of December 31, 2022 were $70.1 million, as compared to $82.6 million as of December 31, 2021, and reflected the receipt of $20.0 million from the term loan with Silicon Valley Bank in February 2022. Based on current plans and assumptions, the Company expects that its existing cash and cash equivalents will be sufficient to fund its current operating plan into the second quarter of 2024.

08:06 EDT Nisun International signs agricultural product procurement agreement - Nisun International's controlled affiliate, Fintech Supply Chain Management Shandong, has entered into a wheat flour sales and purchase agreement with Shandong Binliang Industrial, a company engaged in the purchase and sale of food additives, feed ingredients, grain, edible agricultural products, pre-packed food, primary agricultural products, and related storage and warehousing services. The agreement represents an initiative to increase presence and accelerate business growth in the market of commodity wheat flour. Based on the orders placed by supply chain customers, Nisun would inform Binliang of the purchased quantity, delivery date, and other requirements one day in advance and pay the full amount for the goods within three business days of receiving the delivery note.

08:04 EDT Baijiayun to acquire Beijing Hydrogen - Baijiayun entered into an equity acquisition agreement with Wei Qu, Beijing Hydrogen Information, and three other minority investors in Beijing Hydrogen Data Information to acquire 100% equity ownership of the target company for a total consideration of RMB107.7M, approximately $15.7M, payable in three installments in cash and restricted shares of Baijiayun. The closing of the transaction is expected to take place by the end of March. Founded in 2014 and backed by venture capital, Beijing Hydrogen is a big-data based service and brand management service provider in China, specializing in providing data analysis tools and market data reports for enterprise clients in areas of media and opinion management as part of overall sales and marketing functions.

08:00 EDT Peabody Energy provides update on Shoal Creek Mine - Peabody provided an update following yesterday's fire at Shoal Creek Mine near Birmingham, Alabama. Peabody is continuing to work with the Mine Safety and Health Administration on a reentry plan. Gas monitoring of exhaust air is showing acceptable air quality and atmospheric conditions within the mine. Shoal Creek is in a ramp-up period throughout 2023 and expecting delivery of a new longwall kit during the second half of the year. As a result, Peabody does not expect the current incident to have a material impact on the company's 2023 financial results. Shoal Creek has approximately 419 employees and is a production-stage underground longwall metallurgical coal mine located 35 miles west of Birmingham, Alabama, USA. The mine extracts coal from the Mary Lee and Blue Creek coal seams at depths of 1,000 to 1,300 feet. The Shoal Creek Mine produced approximately 800,000 tons of coal in 2022.

07:51 EDT F45 Training names Tom Dowd CEO, Mark Wahlberg as Chief Brand Officer - F45 Training Holdings announced that it has strengthened its leadership team with the naming of a new Chief Executive Officer and Chief Brand Officer who together bring to F45 highly relevant expertise and a proven track record of building successful brands worldwide. These key appointments follow the Company's recent announcement of $90M in new financing to improve its balance sheet and drive the business forward. Tom Dowd has been appointed F45's new CEO, effective immediately. He succeeds outgoing interim CEO Ben Coates, who remains on the Company's Board of Directors. Mr. Dowd is a seasoned operator who spent 25 years at GNC Holdings in a variety of executive leadership roles and, more recently, co-founded Performance Inspired , a leading active lifestyle nutrition company. Mr. Dowd was one of the early investors in F45. "Tom has significant experience building successful franchise model and consumer goods businesses, cultivating globally resonant lifestyle brands, and developing high-performing teams, making him well suited to lead F45 into the future," said Gene Davis, Chairman of F45's Board. "We are delighted to bring Tom onboard to help further refine F45's go-forward business strategy to deliver sustainable growth, enhance opportunities for our franchisees and team, and drive long-term value for shareholders."

07:50 EDT CVS Health now sees closing Oak Street Health acquisition in 1H23 - In a regulatory filing, CVS Health (CVS) said it now expects to close the acquisition of Oak Street Health (OSH) in the first half of 2023. On its first quarter 2023 earnings call, scheduled for May 3, 2023, the Company expects to provide an update to its full year 2023 guidance to reflect: year-to-date performance and trends; the accretive impacts of the acquisition of Signify Health, Inc., which closed on March 29, 2023; the dilutive impacts of the Oak Street Health acquisition; and the associated interest expense impacts related to the financing for both acquisitions. Although the company has not updated its previously disclosed long-term adjusted earnings per share targets, the impacts associated with these two acquisitions were previously assumed in the company's adjusted earnings per share targets for 2024 and 2025.

07:48 EDT Vertical Aerospace reaches 'significant' certification milestones, including DOA - Vertical Aerospace announces further progress on its path to certification for the VX4, including securing the first ever Design Organization Approval DOA issued to an eVTOL manufacturer by the UK Civil Aviation Authority. Design Organization Approval UK and European aerospace companies cannot hold a Type Certificate without being granted a DOA. The DOA authorises Vertical to conduct design activities and issue design approvals within the DOA's scope of approval. As an approved Design Organization, Vertical will have increasing authority and privileges as we progress through the design and certification program of the VX4. This approval means the CAA is satisfied that Vertical has the capability to design a safe and reliable aircraft and aviation-related products to the highest standards. This is expected to streamline the steps towards obtaining Type Certification. The process for achieving DOA involved a rigorous assessment of Vertical's procedures, its quality management system, the competence of its technical workforce, and the necessary facilities and equipment to support the design activities to certify the VX4 aircraft. Certification progress Earlier this month, the CAA announced its intention to adopt European Union Aviation Safety Agency's EASA Means of Compliance to SC-VTOL, the standards against which European and now UK manufacturers will design eVTOLs. Vertical continues working closely with the CAA on the Type Certification of its VX4 aircraft, having recently submitted its certification basis proposal to the regulator.

07:46 EDT Ra Medical Systems appoints Steven Passey as CFO - Ra Medical Systems announced the appointment of Steven Passey as CFO effective April 1, 2023, replacing Brian Conn, who has been serving as Acting CFO. Mr. Passey was most recently the Chief Financial Officer of QSI Holdings.

07:44 EDT Rekor Systems secures $648,000 contract with parking operator - Rekor Systems announced the sale of Rekor Edge Pro systems and Rekor Scout platform licenses to a large parking operator that has over 15,000 customer locations across all major U.S. cities and Canada. The contract is valued at $648,000.

07:42 EDT Zentek engages Arka BRENStech to develop opportunities in India - Zentek has signed an agreement with Arka BRENStech, pursuant to which BRENStech will act as a local partner to Zentek as it seeks to develop business opportunities in India. Zentek has been working with Mr. Gaurav Kumar, a director of BRENStech, over the last year to understand the Indian market. BRENStech's primary focus under the terms of the Agreement will be to establish sales and distribution opportunities for Zentek masks and HVAC filters and potentially other Zentek products as they become available, however BRENStech will also provide services under the Agreement to connect Zentek with university research facilities, assist with the navigation of applicable regulatory regimes, and to source potential manufacturing partners for Zentek's business opportunities in India and globally.

07:41 EDT Takeda: Phase 4 EARNEST study met primary efficacy endpoint for pouchitis - Takeda confirmed that the New England Journal of Medicine NEJM has published positive data from the Phase 4 EARNEST study of vedolizumab for the treatment of chronic pouchitis. The NEJM article is titled "Vedolizumab for the Treatment of Chronic Pouchitis". A potentially curative surgical option for ulcerative colitis s total proctocolectomy, followed by creation of an ileal pouch anal anastomosis to aid in stool retention. Inflammation of the ileal pouch, pouchitis, can cause fecal incontinence, abdominal discomfort, and bleeding. Chronic pouchitis, defined by symptom duration greater than four weeks, can develop in up to one-fifth of these patients.3 The published results showed the Phase 4 EARNEST study met its primary efficacy endpoint of clinical and endoscopic remission, as measured by modified pouchitis disease activity index at Week 14 in 31% of participants receiving vedolizumab versus 10% receiving placebo This improved outcome compared with placebo was also seen at the equivalent secondary endpoint at Week 34 achieved mPDAI remission compared with 18% on placebo. "Pouchitis is relatively common following pouch surgery for people with ulcerative colitis," said Professor Simon Travis, Translational Gastroenterology Unit and Kennedy Institute, University of Oxford. "Demonstrating the efficacy of a biologic treatment for this inflammatory condition is important for a group of patients who have previously had no treatment option once antibiotics are no longer effective." Beyond mPDAI remission, patients receiving vedolizumab also demonstrated improved clinical response at both Week 14 and Week 34 over placebo, with a difference at Week 14 of 30 p.p. and a Week 34 difference of 22 p.p. "We are committed to advancing treatment and care for patients living with debilitating inflammatory gastrointestinal conditions such as active chronic pouchitis," said Marcelo Freire, Vice President, Global Medical Affairs, Therapeutic Area Head, Gastroenterology, Takeda. "The publication of the latest results from the EARNEST study in the New England Journal of Medicine is great recognition of the work we are doing to reduce the burden of this condition for patients."

07:39 EDT Lizhi's social app TIYA rolls out upgraded MY AI FRIEND chatbot - LIZHI announced that its global social networking platform TIYA App has unveiled a new version of its MY AI FRIEND chatbot to further enrich the app's online companionship experience. The upgraded MY AI FRIEND chatbot is designed for users to create their own online friend, providing a more personalized chatting experience through friendly and engaging in-app conversation. Users can individualize the chatbot - such as its name, gender and skin tone - through customization features. Moving forward, TIYA will leverage LIZHI's experience in the social audio field to continue optimizing, training and fine-tuning the social platform's features, and expand the possible usage scenarios for emotionally rich and fun AI chatbot interactions. For example, TIYA plans to further enhance MY AI FRIEND by adding voice functions utilizing LIZHI's voice AI technologies such as Automatic Speech Recognition and Text-to-Speech.

07:36 EDT SHF Holdings enters agreement to resolve $64.7M in payment obligations - SHF Holdings entered into agreements with Partner Colorado Credit Union, the Company's largest stockholder, resulting in the settlement of the approximately $64.7 million deferred payable owed to PCCU. Under the terms of the Agreement, the Company has agreed to resolve approximately $64.7 million of total payment obligations owed from the September 28, 2022 business combination in exchange for a 5-year, $14.5 million senior secured note bearing a 4.25% annual interest rate and issuance of 11.2 million shares of Class A common stock in the Company.

07:34 EDT Reviva Pharmaceuticals announces upcoming milestones - Anticipated Milestones and Events: Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023; may initiate Phase 2a studies in bipolar disorder, major depressive disorder, and attention deficit hyperactive disorder in second half 2023, subject to the receipt of additional financing; Pursue partnership opportunities for the development of our pipeline; Evaluate grant and other non-dilutive financing opportunities for our product candidates from Federal and State Healthcare Agencies and Foundations

07:29 EDT Laser Photonics partners with Argento Lux - Laser Photonics announced that it has formed a service partnership with Argento Lux to focus on servicing customers and developing business in Texas.Through this partnership, the two entities will provide demonstrations, equipment selling and laser cleaning services. Argento Lux will use a CleanTech 2000-CTH JobSite, which provides a dynamic, cost-effective, time-efficient and adaptable product that will enable Argento Lux to service a wide array of clientele and industries.

07:27 EDT Glatfelter announces completion of refinancing plan - Glatfelter announced that it has completed a series of refinancing transactions that leaves the Company well capitalized and strongly positioned to focus on its turnaround strategy. Summary of Transactions: Glatfelter repaid in full its existing EUR 220,000,000 term loan that would have matured in February 2024, thereby eliminating all near-term debt maturities. The Company amended its existing syndicated revolving credit facility led by PNC Bank National Association, as administrative agent, giving it access to a $250,000,000 revolving credit facility to finance working capital needs and a new covenant structure that reflects the Company's current operating environment and liquidity. The Company closed on the previously announced, 6-year EUR 250,000,000 senior secured term loan facility from certain affiliates of Angelo, Gordon & Co., L.P. With this refinancing, the Company meaningfully extends its debt maturity profile, with no material debt coming due prior to the maturity of the revolving credit facility in September 2026. The financial flexibility gives the Company significant runway to execute its various initiatives before it needs to re-access the debt markets.

07:22 EDT Aldebaran Resources announces early exercise of warrants by Route One - Aldebaran Resources announces that its largest shareholder, Route One Investment Company LLC, together with senior management of the Company, have agreed to an early exercise of 4.7 MM common share purchase warrants. These warrants have an expiry date of May 3, 2023, a strike price of $0.70, and gross proceeds to the Company will be $3.3 MM. An additional 5.3 MM warrants will remain outstanding after the early exercise described above. The Company also advises that it has secured a fourth drill rig, expected to be on site in the coming days.

07:21 EDT Genius Group approved to dual list on Upstream - Genius Group announced its approval to dual list its shares on Upstream. Trading begins on Upstream April 6th, 2023 at 10:00am ET under the ticker symbol GNS. The dual listing on Upstream is designed to provide Genius Group the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in Genius Group.

07:18 EDT Omega Therapeutics announces clinical supply agreement with Roche - Omega Therapeutics (OMGA) announced a clinical supply agreement with Roche (RHHBY) to evaluate OTX-2002, its lead candidate in development for the treatment of MYC-driven hepatocellular carcinoma, HCC, in combination with Roche's anti-PD-L1 therapy, atezolizumab, as part of Omega's Phase 1/2 MYCHELANGELO I clinical trial. "This agreement with Roche represents continued execution of our clinical trial strategy and the next step toward realizing the transformative potential of OTX-2002, a first-in-class epigenomic controller designed to pre-transcriptionally downregulate the MYC oncogene, a historically undruggable target," said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. "In preclinical studies, OTX-2002 demonstrated synergistic antitumor activity with existing standard of care therapies for HCC, including anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors, with minimal impact on safety and tolerability. Through the combination of two orthogonal treatments, OTX-2002 and atezolizumab, a leading anti-PD-L1 therapy, we aim to simultaneously disrupt multiple drivers of cancer progression with the goal of improving treatment outcomes. With Roche's support and partnership, we look forward to assessing the ability of this novel combination approach to enhance antitumor immune response in patients with advanced HCC." Under the terms of this agreement, Roche will supply atezolizumab and Omega will evaluate the combination as part of the overall conduct of the trial.

07:17 EDT Decibel Therapeutics receives European ODD for DB-OTO - Decibel Therapeutics announced that the European Medicines Agency, EMA, Committee on Orphan Medicinal Products, COMP, has issued a positive opinion on orphan drug designation, ODD, for DB-OTO, Decibel's lead gene therapy product candidate designed to provide durable, high quality, physiological hearing to individuals with profound, congenital hearing loss caused by mutations of the otoferlin gene. This opinion was adopted by the European Commission, EC. "We are pleased to receive this important designation from the EC, which supports our conviction that innovative treatments for congenital hearing loss are urgently needed," said Laurence Reid, Ph.D., Chief Executive Officer at Decibel. "Decibel has generated compelling preclinical data showing DB-OTO's potential, and we are on track to initiate CHORD(TM), our global Phase 1/2 clinical trial of DB-OTO, in the first half of this year."

07:14 EDT Chart Industries, Nikola execute strategic partnership - Chart Industries (GTLS) and Nikola Corporation (NKLA) executed a strategic collaboration agreement including liquid hydrogen storage tanks, transport trailers, and the development of new mobile and modular hydrogen refueling stations for quick deployment. This agreement includes additional collaboration on the advancement of hydrogen technology for infrastructure and truck on-board fuel systems. This relationship builds on a previously signed development agreement between Chart and Nikola to work together to develop innovative solutions for the hydrogen electric vehicle market. Through this agreement, Chart is providing fully integrated mobile and modular hydrogen fueling stations for heavy-duty vehicles providing a quickly deployable fueling solution with lower capital requirements. "Nikola is on a mission to transform the transportation industry and by aligning with forward-looking companies such as Chart, we are confident this ambitious goal will be achieved," said Michael Lohscheller, President and CEO, Nikola Corporation. "We know our customers are interested in transitioning to hydrogen quickly and seamlessly. Solutions like Chart's hydrogen transport trailers will play an important part in jump starting a hydrogen ecosystem."

07:13 EDT Anavex announces preliminary results from study of ANAVEX2-73-PDD-EP-001 - Anavex Life Sciences reports preliminary 48-week open-label extension Parkinson's disease dementia ANAVEX(R)2-73-PDD-EP-001 Phase 2 study data which demonstrated longitudinal beneficial effects of ANAVEX(R)2-73 on the prespecified primary and secondary objectives, as well as planned primary and key secondary endpoints which will be utilized in a forthcoming pivotal study of ANAVEX(R)2-73 in Parkinson's disease. The 48-week ANAVEX2-73-PDD-EP-001 Phase 2 study assessed safety, tolerability and efficacy, measuring among others, Movement Disorder Society-Unified Parkinson's Disease Rating Scale Parts I, II, III, REM Sleep Behavior Disorder Screening Questionnaire, Clinical Global Impression - Improvement, as well as cognitive efficacy endpoint Montreal Cognitive Assessment over a 48-week period. Preliminary analysis reveals that ANAVEX(R)2-73was found to be generally safe and well tolerated; and safety findings in this study are consistent with the known safety profile of ANAVEX(R)2-73. In respect to efficacy, across all efficacy endpoints, patients performed better while on ANAVEX(R)2-73. The 48-week Open Label Extension ANAVEX2-73-PDD-EP-001 Phase 2 study was offered to participants after completion of the double-blind placebo-controlled ANAVEX2-73-PDD-001 Phase 2 study. Due to the COVID-19 pandemic, the start of the extension phase was delayed, on average, by approximately 41 weeks at the end of the preceding double-blind placebo-controlled study. This led to a reduced enrollment rate for the extension phase. All efficacy endpoints, which includes the MDS-UPDRS Part II + III and Clinical Global Impression - Improvement measured at the end of trial of the double-blind study, the OLE Baseline, OLE Week 24, and OLE Week 48, showed a worsening during the drug holiday. However, a consistent improvement was observed during the extension phase when patients resumed ANAVEX2-73 treatment.

07:11 EDT Avidity Biosciences provides regulatory update on dystrophy candidate AOC 1001 - Avidity Biosciences provided an update on the Phase 1/2 MARINA trial of AOC 1001 in adults with myotonic dystrophy type 1 - DM1 -, an underrecognized, progressive and often fatal neuromuscular disease with no approved treatment options. In September 2022, the FDA placed a partial clinical hold on new participant enrollment in the Phase 1/2 MARINA clinical trial after reviewing information provided by Avidity related to a serious adverse event reported in a single participant in the 4 mg/kg cohort of the MARINA study. The event was classified by the investigator as drug related. After an extensive investigation, Avidity cannot identify a plausible biological link to any component of AOC 1001, the AOC platform, the transferrin receptor delivery mechanism or reduction of DMPK. In December 2022, the company announced positive data from a preliminary assessment of the Phase 1/2 MARINA study of AOC 1001 demonstrating the first-ever successful targeted delivery of RNA to skeletal muscle, DMPK reduction and splicing improvements, with early signs of clinical activity with improvement in myotonia after just one or two doses of AOC 1001. The top-line data from MARINA will be presented in an oral presentation on April 27, 2023 at the 75th American Academy of Neurology Annual Meeting in Boston. Data supports that the targeted dose range is between 2 mg/kg and 4 mg/kg. Therefore, Avidity will not move forward with the 8 mg/kg dose of AOC 1001. Avidity remains on track to share a first look at the data from the MARINA-OLE study at the end of 2023.

07:10 EDT Diffusion Pharmaceuticals, EIP Pharma announce merger agreement - EIP Pharma and Diffusion Pharmaceuticals announced that the companies have entered into a definitive merger agreement for an all-stock transaction forming a publicly traded, combined company that will focus on the advancement of EIP Pharma's pioneering pipeline of oral stress kinase inhibitors, including its lead drug candidate neflamapimod, which is currently being developed for the treatment of dementia with Lewy bodies, DLB. "This transaction is the result of a thorough strategic review process led by Diffusion's board of directors and executive team initiated in 2022 to identify and negotiate the most compelling, value-enhancing transaction for Diffusion stockholders. From this, EIP Pharma's clinical programs, management team and corporate strategy stood out amongst the many bids we received," said Robert Cobuzzi, Jr., Ph.D., Chief Executive Officer of Diffusion Pharmaceuticals. "We believe this proposed merger is opportunistic and exciting for our shareholders, as EIP has built a robust pipeline of highly needed CNS therapeutic candidates, and we are highly confident in the capabilities of John and his team to support the leadership of the combined company. Taken together, we are thrilled at the prospect of combining our resources and expertise to join EIP's unwavering commitment to treat patients with neurodegenerative diseases."

07:07 EDT MSG Entertainment board approves spin-off of traditional live entertainment unit - Madison Square Garden Entertainment announced that its board of directors has approved the spin-off of its traditional live entertainment business, which is expected to be completed on April 20th. Upon completion of the spin-off transaction, the current parent company will be renamed Sphere Entertainment Co. and will be comprised of the Sphere, MSG Networks and Tao Group Hospitality businesses. The newly formed live entertainment company will take on the name Madison Square Garden Entertainment Corp. and will include a diverse collection of performance venues, the entertainment and sports bookings business, and the Christmas Spectacular Starring the Radio City Rockettes production. Executive Chairman and CEO James L. Dolan said: "With today's announcement, we are one step closer toward our goal of creating two distinct companies, each well positioned to generate long-term value for our shareholders." The distribution will take place on April 20, 2023 to the Company's stockholders of record as of the close of business on April 14, 2023. Each of the Company's common stockholders will receive a distribution of one Class A or Class B share of the new live entertainment company for every share of the Company's Class A or Class B common stock, respectively, held as of the record date, representing approximately 67% of the outstanding shares of the new live entertainment company. Immediately after the spin-off becomes effective, Sphere Entertainment Co. will own approximately 33% of the outstanding shares of the new live entertainment company. The Company's Board of Directors also authorized a $250M share repurchase program for the new live entertainment company's Class A common stock following completion of the spin-off.

07:02 EDT Vigil Neuroscience announces FDA lifts partial clinical hold on VGL101 - Vigil Neuroscience announced that the U.S. Food and Drug Administration has lifted its partial clinical hold on doses greater than 20 mg/kg for VGL101 in its ongoing and future clinical trials in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. VGL101, Vigil's lead product candidate, is currently being studied in IGNITE, a Phase 2 proof-of-concept trial in patients with ALSP as well as in an ongoing Phase 1 single and multiple ascending dose healthy volunteer trial. In November 2022, Vigil reported interim top-line data from the Phase 1 trial in healthy volunteers in the United States and Australia. Based on these data, VGL101 demonstrated favorable safety and tolerability profiles at doses up to 40 mg/kg SAD and 20 mg/kg MAD. The Company expects to report the full data analysis up to 60 mg/kg from the Phase 1 trial in the second half of 2023. In December 2022, Vigil initiated a Phase 2 proof-of-concept clinical trial evaluating VGL101 in patients with ALSP. IGNITE, the first interventional trial in ALSP, is a global Phase 2, open-label trial designed to evaluate the safety and tolerability of VGL101 in up to 15 patients with symptomatic ALSP who have a CSF1R gene mutation. Patients enrolled in the trial will receive an intravenous infusion of 20 mg/kg of VGL101 approximately every 4 weeks for a treatment duration of one year. The Company expects to report six-month interim data from the first six patients in this trial in the second half of 2023. The FDA previously granted Fast Track designation and Orphan Drug designation to VGL101 for the treatment of ALSP.

06:48 EDT Powerbridge acquires majority stake in DTI Group, terms undisclosed - Powerbridge has announced that it has acquired a majority stake of 51% in DTI Group, a platform developer and service provider for digital trade infrastructure in China. The acquisition is a strategic move that contributes to the expansion of Powerbridge's operations by building a digital trade ecosystem.

06:46 EDT AstraZeneca completes agreement with KYM Biosciences for CMG901 - AstraZeneca has completed an exclusive global license agreement with KYM Biosciences Inc.i for CMG901, a potential first-in-class antibody drug conjugate targeting Claudin 18.2, the company announced. "CMG901 is currently being evaluated in a Phase I trial for the treatment of Claudin 18.2-positive solid tumours, including gastric cancer. Preliminary results from the trial have shown an encouraging profile for CMG901, with early signs of anti-tumour activity across the dose levels tested. AstraZeneca has entered into an exclusive global license for the research, development, manufacture and commercialisation of CMG901 for an upfront payment of $63M, with potential development and sales-related milestone payments of up to $1.1B and tiered royalties up to low double digits. The transaction does not impact AstraZeneca's financial guidance for 2023," the company stated.

06:30 EDT Roku to cut about 6% of workforce, or roughly 200 employees - In a regulatory filing, Roku said that on March 29, it approved a restructuring plan to lower the company's year-over-year operating expense growth and prioritize projects that the company believes will have a higher return on investment, which is expected to impact approximately 200 employees, approximately 6% of the company's workforce, and result in the exit and sublease, or cease use, of certain office facilities that the company does not currently occupy. The company estimates that it will incur non-recurring charges of approximately $30M-$35M in connection with the plan, primarily consisting of severance payments, notice pay, employee benefits contributions and related costs and impairment charges related to the exit and sublease, or cease use, of certain office facilities that the company does not currently occupy. The company expects that the majority of the restructuring charges will be incurred in the first quarter of fiscal 2023 and that the implementation of the headcount reductions, including cash payments, will be substantially complete by the end of the second quarter of fiscal 2023.

06:05 EDT High Tide announces purchases of shares by insiders - High Tide announced that certain officers, directors, and consultants led by the company's President and CEO, in the aggregate, acquired 258,921 common shares in the capital of High Tide on the open market between March 24 and March 29 at an average price of $1.59 per Common Share. With these purchases, insiders and certain consultants, in the aggregate, now own or control 7,222,342 Common Shares, representing approximately 9.67% of the company's issued and outstanding Common Shares as of March 29.

05:40 EDT Tenaris to increase participation in T/T group - Tenaris announced that its Brazilian subsidiary Confab Industrial S.A., together with its affiliates Ternium Investments and Ternium Argentina, all of which compose the T/T group within Usiminas control group, have entered into a share purchase agreement to acquire from Nippon Steel Corporation, Mitsubishi and MetalOne, pro rata to their current participations in the T/T group, 68.7M ordinary shares of Usinas Siderurgicas de Minas Gerais at a price of BRL10 per ordinary share. Pursuant to the transaction, Tenaris would pay BRL 110M, or approximately $21M in cash for 11M ordinary shares, increasing its participation in the Usiminas control group to 9.8%. The transaction is subject to approval by Brazil's antitrust authorities and will be financed with cash on hand. The Usiminas control group holds the majority of Usiminas' voting rights and manages the company based on mutual trust. Upon the closing of this transaction, the T/T group will hold an aggregate participation of 61.3% in the control group, with the NSC group and Previdencia Usiminas holding 31.7% and 7.1%, respectively. The Usiminas control group members have also agreed a new governance structure in the best interest of Usiminas. The T/T group will nominate a majority of the Usiminas board of directors, the CEO and four other members of Usiminas board of officers, and ordinary decisions may be approved with a 55% majority of the control group shares. At any time after the second anniversary of the closing of the transaction, the T/T group will have the right to buy the NSC group's remaining interest in the Usiminas control group at the higher of BRL10 per share and the 40-trading day average price per share immediately prior to the date of exercising the option. In addition, the NSC group will have the right, at any time after the closing of the transaction, to withdraw its remaining shares from the control group and sell them in the open market after giving the T/T group the opportunity to buy them at the 40-trading day average price per share immediately prior to the NSC group's notice of withdrawal, as well as the right, at any time after the second anniversary of the closing, to sell such shares to the T/T group at BRL10 per share.

05:34 EDT OKYO Pharma chairman purchases 11,000 ADS for $1.41 - OKYO Pharma announced that it has been notified that Panetta Partners, an entity in which Gabriele Cerrone, the executive chairman has a beneficial interest, purchased 11,000 of the company's ADSs on Nasdaq at a price of $1.41 per ADS.

05:21 EDT BAE Systems, Heart Aerospace announce battery collaboration for ES-30 - BAE Systems and Heart Aerospace announced a collaboration to define the battery system for Heart's ES-30 regional electric airplane. The battery will be integrated into an electric conventional takeoff and landing, or eCTOL, regional aircraft, allowing it to efficiently operate with zero emissions and low noise.

05:10 EDT Ford enters three-party collaboration to advance nickel production in Indonesia - PT Vale Indonesia and China's Zhejiang Huayou Cobalt announced an agreement with Ford, creating a three-party collaboration to advance more sustainable nickel production in Indonesia and help make electric vehicle batteries more affordable. All three companies are making equity investments in the Pomalaa Block High-Pressure Acid Leaching, or HPAL, Project through a definitive agreement celebrated at a ceremony featuring Indonesia President Joko Widodo. The Pomalaa Block HPAL Project will process ore provided by PT Vale Indonesia from its Pomalaa Block mine to produce MHP. This HPAL plant will operate under PT Kolaka Nickel Indonesia in the Pomalaa Block nickel industrial area in Kolaka, Southwest Sulawesi, Indonesia. Subject to regulatory approval, the project could produce up to 120 kilotons per year of contained nickel in the form of mixed hydroxide precipitate, or MHP, a lower-cost nickel product used in EV batteries with nickel-rich cathodes. Pomalaa Block HPAL Project early site preparations have already started, and full construction is expected to start this year, with commercial operations beginning in 2026. The collaboration will deliver materials essential for the auto industry's shift to EVs, enhance Indonesia's EV manufacturing industry and support Ford's plan to deliver a 2M EV production run rate by the end of 2026 and further scale over time. The three-way nickel processing project - together with a separate supply agreement under development with Ford and Huayou for a precursor cathode active material critical to manufacturing lithium-ion batteries - collectively will combine with Ford's other sourced nickel, significantly contributing to support its EV production targets by the end of 2026.